A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers

Trial Profile

A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Leukocyte cell therapy (Primary)
  • Indications Varicose ulcer
  • Focus Registrational; Therapeutic Use
  • Sponsors MacroCure
  • Most Recent Events

    • 19 Aug 2015 Pre-specified, futility analysis conducted by the Data safety Monitoring Board determined that this trial is not expected to meet its primary end point, as per Macrocure media release.
    • 04 Aug 2015 Top-line results from this trial are expected in the first half of 2016 according to a Macrocure media release.
    • 11 May 2015 Results of a futility analysis are expected to be reported in August 2015, according to a Macrocure media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top